Loading…

Angiotensin II protects fibroblast-like synoviocytes from apoptosis via the AT1-NF-κB pathway

Objective. To evaluate the effects of angiotensin II (Ang II) treatment on apoptosis of fibroblast-like synoviocytes (FLS) from patients with osteoarthritis (OA) and rheumatoid arthritis (RA). Methods. AT1 receptor expression was detected by western blotting and flow cytometry. Apoptosis induction w...

Full description

Saved in:
Bibliographic Details
Published in:Rheumatology (Oxford, England) England), 2007-08, Vol.46 (8), p.1252-1257
Main Authors: Pattacini, L., Casali, B., Boiardi, L., Pipitone, N., Albertazzi, L., Salvarani, C.
Format: Article
Language:English
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page 1257
container_issue 8
container_start_page 1252
container_title Rheumatology (Oxford, England)
container_volume 46
creator Pattacini, L.
Casali, B.
Boiardi, L.
Pipitone, N.
Albertazzi, L.
Salvarani, C.
description Objective. To evaluate the effects of angiotensin II (Ang II) treatment on apoptosis of fibroblast-like synoviocytes (FLS) from patients with osteoarthritis (OA) and rheumatoid arthritis (RA). Methods. AT1 receptor expression was detected by western blotting and flow cytometry. Apoptosis induction was quantified by nucleosome ELISA and by TUNEL; cell proliferation was determined by a bromodeoxyuridine (BrdU) incorporation assay. Silencing of p65 NF-κB was obtained by using a specific siRNA. Caspase 3 activation was evaluated by a colorimetric assay and its cleavage by western blotting. Results. AT1 expression resulted comparable in FLS from OA and RA patients. Ang II pre-treatment reduced FLS apoptotic response to serum starvation and nitric oxide (NO) exposure. This protective effect was reverted in the presence of the AT1 receptor antagonist losartan as well as after silencing the expression of NF-κB. Moreover, FLS treatment with the caspase inhibitor z-VAD-fmk cancelled this Ang II effect on apoptosis. Caspase 3 activation was reduced in presence of Ang II. Conclusions. Ang II could represent an important mediator involved in FLS expansion, reducing their capacity to undergo apoptosis, through the activation of NF-κB and the blockage of caspase cascade.
doi_str_mv 10.1093/rheumatology/kem092
format article
fullrecord <record><control><sourceid>proquest_pasca</sourceid><recordid>TN_cdi_proquest_miscellaneous_20299801</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/rheumatology/kem092</oup_id><sourcerecordid>20299801</sourcerecordid><originalsourceid>FETCH-LOGICAL-i293t-b7a36b45e566335776a1f6c412bdaa80e025c9f7bca32038e67cac6828e1291e3</originalsourceid><addsrcrecordid>eNpNkMtOwzAQRSMEEs8vYOMN7FL8SBx7WQqFIh4LQEIssCbGaU2TOMQukF_jI_gmgloBq5nRPXd0daNon-ABwZIdtTOzqCC40k27o7mpsKRr0RZJOI0xY3T9d6fJZrTt_QvGOCVMbEVPw3pqXTC1tzWaTFDT9ocOHhU2b11egg9xaecG-a52b9bpLphebF2FoHFNcN569GYBhZlBwzsSX4_jr89j1ECYvUO3G20UUHqzt5o70f349G50Hl_enE1Gw8vYUslCnGfAeJ6kJuWcsTTLOJCC64TQ_BlAYINpqmWR5RoYxUwYnmnQXFBhCJXEsJ3ocPm3z_-6MD6oynptyhJq4xZeUUylFJj04MEKBK-hLFqotfWqaW0FbaeIkIxhIXpusOTcovlTsfqpW_2vWy3r7g3x0mB9MB-_FmjnimcsS9X5w6O6vbpNkpPRhZLsG8vuiCY</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>20299801</pqid></control><display><type>article</type><title>Angiotensin II protects fibroblast-like synoviocytes from apoptosis via the AT1-NF-κB pathway</title><source>Oxford Journals Online</source><source>Alma/SFX Local Collection</source><creator>Pattacini, L. ; Casali, B. ; Boiardi, L. ; Pipitone, N. ; Albertazzi, L. ; Salvarani, C.</creator><creatorcontrib>Pattacini, L. ; Casali, B. ; Boiardi, L. ; Pipitone, N. ; Albertazzi, L. ; Salvarani, C.</creatorcontrib><description>Objective. To evaluate the effects of angiotensin II (Ang II) treatment on apoptosis of fibroblast-like synoviocytes (FLS) from patients with osteoarthritis (OA) and rheumatoid arthritis (RA). Methods. AT1 receptor expression was detected by western blotting and flow cytometry. Apoptosis induction was quantified by nucleosome ELISA and by TUNEL; cell proliferation was determined by a bromodeoxyuridine (BrdU) incorporation assay. Silencing of p65 NF-κB was obtained by using a specific siRNA. Caspase 3 activation was evaluated by a colorimetric assay and its cleavage by western blotting. Results. AT1 expression resulted comparable in FLS from OA and RA patients. Ang II pre-treatment reduced FLS apoptotic response to serum starvation and nitric oxide (NO) exposure. This protective effect was reverted in the presence of the AT1 receptor antagonist losartan as well as after silencing the expression of NF-κB. Moreover, FLS treatment with the caspase inhibitor z-VAD-fmk cancelled this Ang II effect on apoptosis. Caspase 3 activation was reduced in presence of Ang II. Conclusions. Ang II could represent an important mediator involved in FLS expansion, reducing their capacity to undergo apoptosis, through the activation of NF-κB and the blockage of caspase cascade.</description><identifier>ISSN: 1462-0324</identifier><identifier>EISSN: 1462-0332</identifier><identifier>DOI: 10.1093/rheumatology/kem092</identifier><language>eng</language><publisher>Oxford: Oxford University Press</publisher><subject>Angiotensin II ; Apoptosis ; Biological and medical sciences ; Diseases of the osteoarticular system ; Fibroblast-like synoviocytes ; Inflammatory joint diseases ; Medical sciences ; Miscellaneous. Osteoarticular involvement in other diseases ; NF-κB ; Osteoarthritis ; Rheumatoid arthritis</subject><ispartof>Rheumatology (Oxford, England), 2007-08, Vol.46 (8), p.1252-1257</ispartof><rights>The Author 2007. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org 2007</rights><rights>2007 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=18933088$$DView record in Pascal Francis$$Hfree_for_read</backlink></links><search><creatorcontrib>Pattacini, L.</creatorcontrib><creatorcontrib>Casali, B.</creatorcontrib><creatorcontrib>Boiardi, L.</creatorcontrib><creatorcontrib>Pipitone, N.</creatorcontrib><creatorcontrib>Albertazzi, L.</creatorcontrib><creatorcontrib>Salvarani, C.</creatorcontrib><title>Angiotensin II protects fibroblast-like synoviocytes from apoptosis via the AT1-NF-κB pathway</title><title>Rheumatology (Oxford, England)</title><description>Objective. To evaluate the effects of angiotensin II (Ang II) treatment on apoptosis of fibroblast-like synoviocytes (FLS) from patients with osteoarthritis (OA) and rheumatoid arthritis (RA). Methods. AT1 receptor expression was detected by western blotting and flow cytometry. Apoptosis induction was quantified by nucleosome ELISA and by TUNEL; cell proliferation was determined by a bromodeoxyuridine (BrdU) incorporation assay. Silencing of p65 NF-κB was obtained by using a specific siRNA. Caspase 3 activation was evaluated by a colorimetric assay and its cleavage by western blotting. Results. AT1 expression resulted comparable in FLS from OA and RA patients. Ang II pre-treatment reduced FLS apoptotic response to serum starvation and nitric oxide (NO) exposure. This protective effect was reverted in the presence of the AT1 receptor antagonist losartan as well as after silencing the expression of NF-κB. Moreover, FLS treatment with the caspase inhibitor z-VAD-fmk cancelled this Ang II effect on apoptosis. Caspase 3 activation was reduced in presence of Ang II. Conclusions. Ang II could represent an important mediator involved in FLS expansion, reducing their capacity to undergo apoptosis, through the activation of NF-κB and the blockage of caspase cascade.</description><subject>Angiotensin II</subject><subject>Apoptosis</subject><subject>Biological and medical sciences</subject><subject>Diseases of the osteoarticular system</subject><subject>Fibroblast-like synoviocytes</subject><subject>Inflammatory joint diseases</subject><subject>Medical sciences</subject><subject>Miscellaneous. Osteoarticular involvement in other diseases</subject><subject>NF-κB</subject><subject>Osteoarthritis</subject><subject>Rheumatoid arthritis</subject><issn>1462-0324</issn><issn>1462-0332</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><recordid>eNpNkMtOwzAQRSMEEs8vYOMN7FL8SBx7WQqFIh4LQEIssCbGaU2TOMQukF_jI_gmgloBq5nRPXd0daNon-ABwZIdtTOzqCC40k27o7mpsKRr0RZJOI0xY3T9d6fJZrTt_QvGOCVMbEVPw3pqXTC1tzWaTFDT9ocOHhU2b11egg9xaecG-a52b9bpLphebF2FoHFNcN569GYBhZlBwzsSX4_jr89j1ECYvUO3G20UUHqzt5o70f349G50Hl_enE1Gw8vYUslCnGfAeJ6kJuWcsTTLOJCC64TQ_BlAYINpqmWR5RoYxUwYnmnQXFBhCJXEsJ3ocPm3z_-6MD6oynptyhJq4xZeUUylFJj04MEKBK-hLFqotfWqaW0FbaeIkIxhIXpusOTcovlTsfqpW_2vWy3r7g3x0mB9MB-_FmjnimcsS9X5w6O6vbpNkpPRhZLsG8vuiCY</recordid><startdate>20070801</startdate><enddate>20070801</enddate><creator>Pattacini, L.</creator><creator>Casali, B.</creator><creator>Boiardi, L.</creator><creator>Pipitone, N.</creator><creator>Albertazzi, L.</creator><creator>Salvarani, C.</creator><general>Oxford University Press</general><scope>BSCLL</scope><scope>IQODW</scope><scope>7QP</scope></search><sort><creationdate>20070801</creationdate><title>Angiotensin II protects fibroblast-like synoviocytes from apoptosis via the AT1-NF-κB pathway</title><author>Pattacini, L. ; Casali, B. ; Boiardi, L. ; Pipitone, N. ; Albertazzi, L. ; Salvarani, C.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-i293t-b7a36b45e566335776a1f6c412bdaa80e025c9f7bca32038e67cac6828e1291e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Angiotensin II</topic><topic>Apoptosis</topic><topic>Biological and medical sciences</topic><topic>Diseases of the osteoarticular system</topic><topic>Fibroblast-like synoviocytes</topic><topic>Inflammatory joint diseases</topic><topic>Medical sciences</topic><topic>Miscellaneous. Osteoarticular involvement in other diseases</topic><topic>NF-κB</topic><topic>Osteoarthritis</topic><topic>Rheumatoid arthritis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Pattacini, L.</creatorcontrib><creatorcontrib>Casali, B.</creatorcontrib><creatorcontrib>Boiardi, L.</creatorcontrib><creatorcontrib>Pipitone, N.</creatorcontrib><creatorcontrib>Albertazzi, L.</creatorcontrib><creatorcontrib>Salvarani, C.</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Calcium &amp; Calcified Tissue Abstracts</collection><jtitle>Rheumatology (Oxford, England)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Pattacini, L.</au><au>Casali, B.</au><au>Boiardi, L.</au><au>Pipitone, N.</au><au>Albertazzi, L.</au><au>Salvarani, C.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Angiotensin II protects fibroblast-like synoviocytes from apoptosis via the AT1-NF-κB pathway</atitle><jtitle>Rheumatology (Oxford, England)</jtitle><date>2007-08-01</date><risdate>2007</risdate><volume>46</volume><issue>8</issue><spage>1252</spage><epage>1257</epage><pages>1252-1257</pages><issn>1462-0324</issn><eissn>1462-0332</eissn><abstract>Objective. To evaluate the effects of angiotensin II (Ang II) treatment on apoptosis of fibroblast-like synoviocytes (FLS) from patients with osteoarthritis (OA) and rheumatoid arthritis (RA). Methods. AT1 receptor expression was detected by western blotting and flow cytometry. Apoptosis induction was quantified by nucleosome ELISA and by TUNEL; cell proliferation was determined by a bromodeoxyuridine (BrdU) incorporation assay. Silencing of p65 NF-κB was obtained by using a specific siRNA. Caspase 3 activation was evaluated by a colorimetric assay and its cleavage by western blotting. Results. AT1 expression resulted comparable in FLS from OA and RA patients. Ang II pre-treatment reduced FLS apoptotic response to serum starvation and nitric oxide (NO) exposure. This protective effect was reverted in the presence of the AT1 receptor antagonist losartan as well as after silencing the expression of NF-κB. Moreover, FLS treatment with the caspase inhibitor z-VAD-fmk cancelled this Ang II effect on apoptosis. Caspase 3 activation was reduced in presence of Ang II. Conclusions. Ang II could represent an important mediator involved in FLS expansion, reducing their capacity to undergo apoptosis, through the activation of NF-κB and the blockage of caspase cascade.</abstract><cop>Oxford</cop><pub>Oxford University Press</pub><doi>10.1093/rheumatology/kem092</doi><tpages>6</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1462-0324
ispartof Rheumatology (Oxford, England), 2007-08, Vol.46 (8), p.1252-1257
issn 1462-0324
1462-0332
language eng
recordid cdi_proquest_miscellaneous_20299801
source Oxford Journals Online; Alma/SFX Local Collection
subjects Angiotensin II
Apoptosis
Biological and medical sciences
Diseases of the osteoarticular system
Fibroblast-like synoviocytes
Inflammatory joint diseases
Medical sciences
Miscellaneous. Osteoarticular involvement in other diseases
NF-κB
Osteoarthritis
Rheumatoid arthritis
title Angiotensin II protects fibroblast-like synoviocytes from apoptosis via the AT1-NF-κB pathway
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T11%3A36%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pasca&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Angiotensin%20II%20protects%20fibroblast-like%20synoviocytes%20from%20apoptosis%20via%20the%20AT1-NF-%CE%BAB%20pathway&rft.jtitle=Rheumatology%20(Oxford,%20England)&rft.au=Pattacini,%20L.&rft.date=2007-08-01&rft.volume=46&rft.issue=8&rft.spage=1252&rft.epage=1257&rft.pages=1252-1257&rft.issn=1462-0324&rft.eissn=1462-0332&rft_id=info:doi/10.1093/rheumatology/kem092&rft_dat=%3Cproquest_pasca%3E20299801%3C/proquest_pasca%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-i293t-b7a36b45e566335776a1f6c412bdaa80e025c9f7bca32038e67cac6828e1291e3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=20299801&rft_id=info:pmid/&rft_oup_id=10.1093/rheumatology/kem092&rfr_iscdi=true